Press Releases

14 August 2020

Results of Placing

13 August 2020

Interim Results for the Six Months ended 30 June 2020

27 July 2020

Acacia Pharma Advances Preparations for US Launch of BARHEMSYS®

15 July 2020

Acacia Pharma Assigned US License for BYFAVO™ (remimazolam) by Cosmo Pharmaceuticals NV

02 July 2020

Acacia Pharma Announces US FDA Approval of BYFAVO™ (remimazolam) for injection for the Induction and Maintenance of Procedural Sedation

01 June 2020

Acacia Pharma Announces Debt for Equity Swap with Cosmo Pharmaceuticals

07 April 2020

Alessandro Della Chà Appointed as Director of Acacia Pharma Group plc

12 March 2020

Acacia Pharma Announces Brief Extension of FDA Review Period for NDA for BYFAVO™  

02 March 2020

Acacia Pharma Announces Changes to its Officers and Board of Directors

02 March 2020

Results for the Year ended 31 December 2019

27 February 2020

Acacia Pharma Announces US FDA Approval of BARHEMSYS® (amisulpride) for the Treatment and Prevention of Postoperative Nausea and Vomiting (PONV)

24 January 2020

Acacia Pharma Wins BEL Small Company of the Year 2019

13 January 2020

Acacia Pharma Announces Planned CFO Succession

10 January 2020

Acacia Pharma Enters into Strategic In-licensing, Investment and Loan Transaction with Cosmo Pharmaceuticals N.V.

26 September 2019

Acacia Pharma Announces New BARHEMSYS® PDUFA Target Date of 26 February 2020

05 September 2019

Interim Results for the Six Months ended 30 June 2019

18 July 2019

Founder Dr. Julian Gilbert steps down - Michael Bolinder, Chief Commercial Officer, becomes CEO in Planned Succession

12 July 2019

Editorial on Positive Data for BARHEMSYS® Treatment of PONV Published in Anesthesia & Analgesia

08 July 2019

Acacia Pharma Plans to Resubmit the BARHEMSYS® NDA in Q3 2019

03 June 2019

Annual General Meeting Results and Statement

10 May 2019

Acacia Pharma’s BARHEMSYS® Significantly Improves Post-operative Nausea & Vomiting (PONV) in Rescue Treatment of Ambulatory Patients

07 May 2019

Notice of Annual General Meeting

03 May 2019

Acacia Pharma Receives Complete Response Letter from FDA for BARHEMSYS®

25 April 2019

Positive Phase 3 BARHEMSYS® Rescue Treatment Data to be Presented at the Annual Congress of Enhanced Recovery and Perioperative Medicine

27 February 2019

Results for the year ended 31 December 2018